In breast cancer, the expression of TOLLIP was heterogeneous; in 25% of tumors, the expression was higher than in normal tissue, but in 35%, the expression was lower than in the control and increased during breast cancer progression. This evidence concerns the gene TOLLIP and breast cancer.